Detection of transrenal DNA for the diagnosis of pulmonary tuberculosis and treatment monitoring

Labugger, Ines; Heyckendorf, Jan; Dees, Stefan; Häussinger, Emilia; Herzmann, Christian; Kohl, Thomas A.; Richter, Elvira; Rivera-Milla, Eric; Lange, Christoph

doi:10.1007/s15010-016-0955-2

Cited by 39 publications

(53 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Molecular tests such as the GeneXpert (Cepheid, USA) or the line-probe assays (Hain Life Sciences, Nehren, Germany) are commercially available as rapid diagnostic methods that permit drug-resistance prediction for important first-and second-line drugs (76,77). As an alternative, transrenal DNA, and lipoarabinomannan (LAM) detection in urine have been described to diagnose active tuberculosis in people living with HIV (78)(79)(80). Screening for tuberculosis with a LAM urine assay in African people living with HIV and low CD4 count lead to a significant decrease in mortality (81).…”

Section: Iv: Biomarker Based Treatment Decisionsmentioning

confidence: 99%

Perspective for Precision Medicine for Tuberculosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Tuberculosis is a bacterial infectious disease that is mainly transmitted from human to human via infectious aerosols. Currently, tuberculosis is the leading cause of death by an infectious disease worldwide. In the past decade, the number of patients affected by tuberculosis has increased by ∼20 percent and the emergence of drug-resistant strains of Mycobacterium tuberculosis challenges the goal of elimination of tuberculosis in the near future. For the last 50 years, management of patients with tuberculosis has followed a standardized management approach. This standardization neglects the variation in human susceptibility to infection, immune response, the pharmacokinetics of drugs, and the individual duration of treatment needed to achieve relapse-free cure. Here we propose a package of precision medicine-guided therapies that has the prospect to drive clinical management decisions, based on both host immunity and M. tuberculosis strains genetics. Recently, important scientific discoveries and technological advances have been achieved that provide a perspective for individualized rather than standardized management of patients with tuberculosis. For the individual selection of best medicines and host-directed therapies, personalized drug dosing, and treatment durations, physicians treating patients with tuberculosis will be able to rely on these advances in systems biology and to apply them at the bedside.

show abstract

Section: Iv: Biomarker Based Treatment Decisionsmentioning

confidence: 99%

Perspective for Precision Medicine for Tuberculosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, since this marker yields positive results before treatment initiation where higher overall bacterial loads are to be found it may not be suitable to serve during late time‐points during therapy when most bacteria are already killed. Specific mycobacterial PCRs from sputum and urine were analyzed to serve as markers for therapy response . Although mycobacterial DNA from these compartments were identified even late after therapy initiation, the pathogen's viability cannot be determined, which questions these results' relevance for the clinic.…”

Section: Biomarker Guided Treatment Decisionsmentioning

confidence: 99%

Perspectives for personalized therapy for patients with multidrug‐resistant tuberculosis

et al. 2018

View full text Add to dashboard Cite

According to the World Health Organization (WHO), tuberculosis is the leading cause of death attributed to a single microbial pathogen worldwide. In addition to the large number of patients affected by tuberculosis, the emergence of Mycobacterium tuberculosis drug-resistance is complicating tuberculosis control in many high-burden countries. During the past 5 years, the global number of patients identified with multidrug-resistant tuberculosis (MDR-TB), defined as bacillary resistance at least against rifampicin and isoniazid, the two most active drugs in a treatment regimen, has increased by more than 20% annually. Today we experience a historical peak in the number of patients affected by MDR-TB. The management of MDR-TB is characterized by delayed diagnosis, uncertainty of the extent of bacillary drug-resistance, imprecise standardized drug regimens and dosages, very long duration of therapy and high frequency of adverse events which all translate into a poor prognosis for many of the affected patients. Major scientific and technological advances in recent years provide new perspectives through treatment regimens tailor-made to individual needs. Where available, such personalized treatment has major implications on the treatment outcomes of patients with MDR-TB. The challenge now is to bring these adances to those patients that need them most.

show abstract

“…Studies of Aspergillus PCR have demonstrated that Aspergillus DNA in serum remains relatively stable for the first week after treatment, and clearance by 2-3 weeks may be associated with favorable treatment outcomes (Imbert et al, 2016). Furthermore, in a study of urine cfDNA for tuberculosis, pathogen cfDNA increased with treatment (Labugger I et al, 2017). Further investigation will be needed to understand the potentially unique biologic variances of different organisms and to better understand the effects of antifungal treatment on the dynamics of pathogen cell-free DNA to interpret the performance of plasma NGS in patients with invasive fungal infections.…”

Section: Non-invasive Biomarkers For Ifi Including Thementioning

confidence: 99%

Liquid biopsy for infectious diseases: Sequencing of cell-free plasma to detect pathogen DNA in patients with invasive fungal disease

Hong¹,

Blauwkamp²,

Kertesz³

et al. 2018

Preprint

View full text Add to dashboard Cite

Diagnosis of life-threatening deep-seated infections currently requires invasive sampling of the infectedtissue to provide a microbiologic diagnosis. These procedures can lead to high morbidity in patients and add to healthcare costs. Here we describe a novel next-generation sequencing assay that was used to detect pathogen-derived cell-free DNA in peripheral blood of patients with biopsy-proven invasive fungal infections. The non-invasive nature of this approach could provide rapid, actionable treatment information for invasive fungal infections when a biopsy is not possible.

show abstract

Detection of transrenal DNA for the diagnosis of pulmonary tuberculosis and treatment monitoring

Cited by 39 publications

References 26 publications

Perspective for Precision Medicine for Tuberculosis

Perspective for Precision Medicine for Tuberculosis

Perspectives for personalized therapy for patients with multidrug‐resistant tuberculosis

Liquid biopsy for infectious diseases: Sequencing of cell-free plasma to detect pathogen DNA in patients with invasive fungal disease

Contact Info

Product

Resources

About